P-133 Clinical responses in pancreaticobiliary cancer patients who received bintrafusp alfa (BA) or BA plus CXCR1/2 inhibitor (SX-682) plus CEA/MUC1-targted vaccine (CV301)
Year: 2022
Type: conference-abstract
Source: Annals of Oncology
Institutions: National Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), The University of Texas MD Anderson Cancer Center, University of California Davis Medical Center, Royal North Shore Hospital, Merck Healthcare KGaA, Darmstadt (Germany), Bavarian Nordic (Germany), Syntrix Biosystems (United States), Merck Biopharma Co., Ltd. (Japan)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4283779255